Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 16/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.48 |
| ▸ | GAK | O14976 | 1/20 | 0.48 |
| ▸ | PRKACG | P22612 | 1/20 | 0.48 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | IDH1 | O75874 | 4/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30500997 | 0.84 | PIK3CA (0.51) | PIK3CAPIK3CDPIK3CGPIK3CBGAK | |
| SCHEMBL15801542 | 0.84 | PIK3CA (0.51) | PIK3CAPIK3CDPIK3CGPIK3CBGAK | |
| SCHEMBL21181792 | 0.82 | PIK3CA (0.56) | PIK3CAPIK3CDPIK3CGPIK3CBGAK | |
| SCHEMBL16042561 | 0.80 | IDH1 (0.49) | PIK3CAPIK3CDPIK3CGPIK3CBGAK | |
| SCHEMBL16043754 | 0.80 | PIK3CA (0.52) | PIK3CAPIK3CDPIK3CGPIK3CBGAK | |
| SCHEMBL20294508 | 0.79 | PIK3CA (0.54) | PIK3CAPIK3CDPIK3CGPIK3CBGAK | |
| SCHEMBL15550748 | 0.79 | PIK3CA (0.56) | PIK3CAPIK3CDPIK3CGPIK3CBGAK | |
| Hydrochloric Acid SCHEMBL16042980 | 0.79 | IDH1 (0.49) | PIK3CAPIK3CDPIK3CGPIK3CBGAK | |
| SCHEMBL20025608 | 0.78 | PIK3CA (0.55) | PIK3CAPIK3CDPIK3CGPIK3CBGAK | |
| SCHEMBL1938956 | 0.78 | PIK3CA (0.51) | PIK3CAPIK3CDPIK3CGPIK3CBGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10112931-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2018-10-30 | — | — | US | disclosed |
| US-20180051015-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2018-02-22 | — | — | US | disclosed |
| EP-2970240-B1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2018-01-10 | — | — | EP | disclosed |
| US-9688672-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| US-20160318915-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2016-11-03 | — | — | US | disclosed |
| US-9434719-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2016-09-06 | — | — | US | disclosed |
| US-20150152093-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| US-20140275083-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275083-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | PIK3CA 517/4885PIK3CD 1190/4885PIK3CG 1650/4885 |
| US-20180051015-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | PIK3CA 517/4885PIK3CD 1190/4885PIK3CG 1650/4885 |
| US-20160318915-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | PIK3CA 517/4885PIK3CD 1190/4885PIK3CG 1650/4885 |
| US-20150152093-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | PIK3CA 517/4885PIK3CD 1190/4885PIK3CG 1650/4885 |
| US-10112931-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | IDH1, IDH3B, IDH3A | PIK3CA 517/4885PIK3CD 1190/4885PIK3CG 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.